Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wen-Hann Tan, Children's Hospital Boston
ClinicalTrials.gov Identifier:
NCT00829439
First received: January 26, 2009
Last updated: October 10, 2012
Last verified: October 2012

January 26, 2009
October 10, 2012
January 2009
June 2010   (final data collection date for primary outcome measure)
Maximum dose of levodopa/carbidopa that can be tolerated (without any dose limiting toxicity) by at least 5 out of 6 different subjects. [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00829439 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome

This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome.

It has been hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in children with Angelman syndrome.

Data from this study will be used to design a phase II trial to determine the efficacy of levodopa in treating children with Angelman syndrome.

Levodopa is a prodrug that "delivers" dopamine to the brain. It is usually given with carbidopa, a peripheral decarboxylase inhibitor, to increase the bioavailability of levodopa. Animal studies have suggested that levodopa can reverse the excess phosphorylation of some enzymes involved in synaptic and neuronal function, including calcium/calmodulin-dependent kinase type 2 (CaMKII).

Recently, it was shown that excess phosphorylation of CaMKII may be responsible for some of the neurological deficits seen in Angelman syndrome. Therefore, it is hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in children with Angelman syndrome.

Although many children have used levodopa for a variety of medical conditions over the last 30 years, it has not been approved by the Food and Drug Administration (FDA) for use in children, and it has not been formally studied in children with Angelman syndrome, so we do not know what dose of levodopa is most appropriate for children with Angelman syndrome.

Therefore, the purpose of this study is to find out the highest dose of levodopa that children with Angelman syndrome can tolerate without any serious side effects.

Once we know the dose of levodopa that can be tolerated by children with Angelman syndrome, we will conduct a larger follow-up study to find out whether levodopa will lead to an improvement in their development and tremor.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Angelman Syndrome
Drug: Levodopa/Carbidopa (4:1)

Dosages are based on levodopa.

Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.

Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.

Other Names:
  • Sinemet
  • L-dopa
Experimental: Levodopa/Carbidopa

Other Names:

Sinemet L-dopa

Dosages are based on levodopa.

Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.

Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.

Intervention: Drug: Levodopa/Carbidopa (4:1)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
June 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Angelman syndrome, confirmed by molecular testing
  • Must be willing to come for research visit on 2 days, exactly 1 week apart

Exclusion Criteria:

  • On levodopa, carbidopa, or any dopamine agonists in the 2 weeks prior to participation
  • Other medical conditions that may be associated with developmental or cognitive delays
  • More than 2 clinical seizures per month
  • Used monoamine oxidase (MAO) inhibitors within the last 2 weeks
  • Used phenytoin within the last 2 weeks
  • Used phenothiazines, butyrophenones, and thioxanthenes within last 2 weeks
  • Hypersensitive to levodopa or carbidopa
  • Cardiovascular disease or instability
  • Respiratory diseases, including asthma, emphysema, chronic cough, and shortness of breath
  • Liver disease
  • Stomach or intestinal ulcers
  • Kidney disease
  • Hematological problems, including anemia, leucopenia, and thrombocytopenia
  • Used investigational drugs/interventions within the past three months
Both
4 Years to 12 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00829439
08-10-0490
Yes
Wen-Hann Tan, Children's Hospital Boston
Children's Hospital Boston
Not Provided
Principal Investigator: Wen-Hann Tan, BMBS Children's Hospital Boston
Children's Hospital Boston
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP